GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence (GOT)

Tislelizumab Combined with GEMOX (GOT) Applied As Neoadjuvant Regimen for Patients of Resectable Intrahepatic Cholangiocarcinoma with High-risk Factors of Recurrence: a Single Arm, Single Center, Prospective, Explorative Clinical Trail.

Intrahepatic cholangiocarcinoma (ICC) arises from the epithelial cells of bile ducts and occurs proximal to the segmental biliary ducts. ICC is highly aggressive, long-term survival only can be achieved in patients with R0 surgical resection. Large diameter of tumor, multiple tumors, preoperative carbohydrate antigen(CA)19-9 elevated, tumors invaded adjacent blood vessels and preoperative radiology hints suspected regional lymph node metastasis were considered as high-risk factors of recurrence in the previous study. Chemotherapy can trigger antigen release and induces strong anti-tumor effects of T cells due to cytotoxic cell death. Immune checkpoint inhibitors can relieve tumor immunosuppressive microenvironment. Hence, we aim to investigate objective response rate and R0 resection rate and survival rate of patients with high-risk factors of recurrence who receives Tislelizumab combined with GEMOX regimen(GOT) as a neoadjuvant therapy.

Study Overview

• Status: Recruiting
• Conditions: Intrahepatic Cholangiocarcinoma
• Intervention / Treatment: Drug: Tislelizumab combined with GEMOX (GOT) regimen

• Study Type: Interventional
• Enrollment (Estimated): 20
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Chaoqun Fei; Phone Number: +086-0571-88122564; Email: ec@zjcc.org.cn

Study Locations

• China
  • Zhejiang
    • Hangzhou, Zhejiang, China, 310022
      • Not yet recruiting
      • 1# Banshan East Rd. Zhejiang cancer hospital
      • Contact: Yuhua - Zhang, M.D.; Phone Number: +86-0571-88128058; Email: drzhangyuhua@126.com
      • Contact: Jia - Wu; Phone Number: +86-0571-88128052; Email: tkds123@qq.com
    • Hanzhou, Zhejiang, China, 310000
      • Recruiting
      • Jia Wu
      • Contact: Jia Wu; Phone Number: 086-0571-88128058; Email: tkds123@qq.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. 18-75 yo;
2. Patients of Pathological confirmed intrahepatic cholangiocarcinoma who has never received systemic therapy including chemotherapy, immunotherapy, target therapy and other anti-cancer therapy;

3. Patients of resectable ICC with high risk recurrent factors:

   ①Maximum diameter greater than 5cm or multiple tumors.

   ②Preoperative CA19-9 greater than 200 Unit(U)/mL

   ③Tumors invaded adjacent blood vessels

   ④Preoperative radiology hints suspected regional lymph node metastasis.

   ⑤Tumor tissues confirmed by CT or MRI, at least one measurable lesion exists according to RECIST v1.1.

4. Eastern Cooperative Oncology Group(ECOG)-Performance status(PS) score is 0 before first drug administration;
5. Child-Pugh classification is class A;
6. Estimated overall survival is greater than 16 weeks;

7. The level of organ function meets the criteria and can tolerate surgery before the first treatment. Main organs meet the criteria as below:

   haemoglobin≥90g/L，Neutrophil count≥1.5×10⁹/L，Platelet count≥100×10⁹/L；Aspartate or alanine aminotransferase≤5 upper limits of normal(ULN），alkaline phosphatase≤2.5 ULN，Serum albumin≥30g/L；serum creatinine<1.5 ULN；International normalized ratios（INR）≤2 or Prothrombin time（PT）exceed ULN≤6s；Creatinine clearance≥60 mL/min.

8. Male and female subjects with potential fertility had to agree to the use of effective contraceptive methods throughout the study period；
9. Sign an informed consent form agreeing to provide previously preserved specimens of tumor tissue or fresh detection of tumor lesions.

Exclusion Criteria:

1. Patient with non-intrahepatic cholangiocarcinoma；
2. Anti-cancer therapy or surgery such as radiotherapy, radiofrequency ablation, interventions in 28 days prior to the first dose of the study (except for previous non-tumor-related surgeries and diagnostic biopsies)；
3. Distant metastasis；
4. hepatitis B virus (HBV) DNA>2000 copies/ml, hepatitis C virus (HCV) RNA>1000;
5. Long-term glucocorticoid users require long-term systemic hormones (equivalent to >10 mg Prednisone/day) or any other form of immunosuppressive therapy；
6. Clinically significant bleeding or bleeding tendencies within 3 months prior to enrollment or on thrombolytic or anticoagulant therapy；
7. Patients with complete bowel obstruction and incomplete intestinal obstruction that require treatment, but patients who have been relieved of obstruction by ostomy or stent placement can be enrolled；
8. Active severe clinical infections (> grade 2, NCI-CTCAE version 5.0), including active TB; Have a history of active TB infection at least 1 year before enrolment, have not received regular anti-tuberculosis (TB) treatment or are still active; active, known or suspected autoimmune disease;
9. Uncontrolled diabetes mellitus (fasting blood glucose ≥10 mmol/L), severe lung disease (eg, acute lung disease, pulmonary fibrosis that affects lung function, interstitial lung disease). except for recovered radiation pneumonia);
10. Clinically significant cardiovascular diseases; With hypertension, antihypertensive drugs cannot be well controlled (systolic blood pressure≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg);
11. Patient who are receiving renal replacement therapy；
12. History of other malignancies in the last 5 years. With the exception of carcinoma of the skin basal cells that have been cured or carcinoma in situ in the cervix;
13. Others situations are not expected to tolerate surgical treatment；
14. People with allergic reactions to any component of the drug under study;
15. There are other unsuitable candidates for clinical trials, such as alcohol dependence, mental illness, pregnancy (or lactation).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental arm; Tislelizumab combined with GEMOX (GOT) regimen	Drug: Tislelizumab combined with GEMOX (GOT) regimen; Tislelizumab 200mg on day 1；Gemcitabine 1000mg/m2 on day 1、8；Oxaliplatin 135mg/m2 on day 1；cycle 3 weeks; Other Names: Gemcitabine; Oxaliplatin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective response rate (ORR)	The proportion of patients who achieved complete response (CR) and partial response(PR) after GOT regimen neoadjuvant treatment according to Response Evaluation Criteria In Solid Tumors (RECIST) v1.1.	Up to 6 cycle treatment (each cycle is 21 days), an average of 18 weeks.
R0 resection rate	The proportion of patients who achieved pathological negative surgical margin after GOT regimen neoadjuvant treatment.	Up to pathological report come out, an average of 20 weeks.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Disease control rate (DCR)	The proportion of patients who achieved complete response (CR), partial response (PR) and stable disease (SD) after GOT regimen neoadjuvant treatment according to RECIST v1.1.	Up to 6 cycle treatment (each cycle is 21 days), an average of 18 weeks.
Recurrence free survival	The time between the date of patients underwent radical resection and the date of radiographic recurrence as defined by RECIST1.1.	From date when patients are received radical resection until the date of first documented recurrence radiologically, assessed at least 12 months.
Overall survival	The time between the date of patients underwent radical resection and death from any cause.	From date when patients are received radical resection until the date of death from any cause, assessed at least 12 months.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to response (TTR)	The time between the date of patients received first treatment and the date of first documented complete or partial response.	From date of received first treatment to first achieved complete or partial response, up to 18 weeks.
Time to operation (TTO)	The time between the date of patients received first treatment and the date of patients received operation.	From date of received first treatment to date of surgery, an average of 20 weeks.

Collaborators and Investigators

• Sponsor: Zhejiang Cancer Hospital
• Investigators: Study Chair: Yuhua - Zhang, M.D., Zhejiang Cancer Hospital

Study record dates

Study Major Dates

• Study Start (Actual): May 5, 2023
• Primary Completion (Estimated): November 30, 2025
• Study Completion (Estimated): December 1, 2025

Study Registration Dates

• First Submitted: September 19, 2022
• First Submitted That Met QC Criteria: September 24, 2022
• First Posted (Actual): September 28, 2022

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 9, 2025
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Keywords: Gemcitabine; cholangiocarcinoma; Neoadjuvant; Oxaliplatin; Tislelizumab
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms; Disease Attributes; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Carcinoma; Recurrence; Cholangiocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Agents; Molecular Mechanisms of Pharmacological Action; Antimetabolites, Antineoplastic; Antimetabolites; Oxaliplatin; Gemcitabine; Tislelizumab
• Other Study ID Numbers: ZhangYH

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No